MGX-101
sdAb
Solid Tumors
Target: CCR8
Lead immuno-oncology program targeting TME/Treg biology.
- Differentiation: First in Class / Novel MoA
Biology-driven discovery
Precision Single-Domain Antibody Therapeutics
for Immuno-Oncology and Complex Targets
AI-assisted biology-driven innovation with real-world impact. Advancing next-generation sdAb therapeutics through biology-aware discovery and data-driven antibody design.
3
Active programs
2
Discovery platforms
IO
Lead therapeutic focus
About us
Designed around the biology that matters.
mAbGenEx is built around PrecinAb™, a biology-aware antibody discovery platform. Instead of generating large antibody panels and hoping biology cooperates, we begin by identifying the epitope most likely to deliver specificity, safety, and functional impact.
Epitope-first strategy
Prioritizes the right binding region before costly discovery and engineering cycles.
AI + deep biology
Combines ML-guided design, structural logic, and experimental validation.
Translational intent
Focused on complex target biology, solid tumors, and programs where precision matters early.
Pipeline
Focused programs across tumor microenvironment modulation, antivenom innovation, and neglected tropical disease diagnostics.
Therapeutics
MGX-102
sdAb
Anti-snake Venom
Targets: PLA2, Btx
Next-gen monoclonal antivenom, moving beyond polyclonal approaches.
- Differentiation: Monoclonal sdAb Cocktail
Diagnostics
MGX-103
sdAb
NTD Diagnostic
Indication: Lymphatic Filariasis
Single-domain antibody-enabled diagnostic program for neglected tropical disease detection.
- Differentiation: High-sensitivity sdAb detection
Technology
Two Complementary Discovery and Design Engines.
PrecinAb™ and OptinAb™ work together to connect in-Silico precision with experimental screening and developability.
PrecinAb™
Precision Antibodies Redefined
Biology-Aware Antibody Discovery
Identifies the right target, epitope, and antibody concepts using biological insight and computational design.
- Epitope-first strategy
- Functional biology prioritization
- Precision candidate generation
OptinAb™
Optimized Antibodies
Experimental Optimization Platform
Converts promising antibody concepts into optimized therapeutic leads through advanced screening and engineering.
- Natural repertoire-inspired libraries
- Selectivity-focused screening
- Affinity and developability optimization
Leadership & advisory
Suresh Chintalapati, PhD, MBA
Founder, CEO and Chairman
With over 25 years of experience in molecular biology, immunology, and biotechnology leadership, he is dedicated to translating cutting-edge science into innovative healthcare solutions with global impact.
LinkedIn
Lakshmipathi Khandrika, PhD
Director R&D
With over 22 years of experience in molecular biology, cell biology, and oncology research, he is committed to translating scientific discoveries into impactful healthcare innovations.
LinkedIn
Satyamurthy Kundharapu, PhD
Senior Scientist
With over 15 years of experience in structural biology, protein chemistry, and therapeutic antibody engineering, he is committed to translating scientific innovation into next-generation biologics.
LinkedIn
Aswani Valiveti, PhD, MBA
Advisory Board Member
Advises mAbGenEx on innovation positioning and strategic partnerships across life science research and enterprise formation.
LinkedIn
Sadanand Vodala, PhD
Advisory Board Member
Translational medicine scientist specializing in hematology, solid tumor oncology, and biomarker discovery.
LinkedIn
Shyam Sarikonda, PhD
Advisory Board Member
Immunologist and biomarker development leader with 15+ years advancing cell therapies and immuno-oncology.
LinkedIn
Momentum
CCR8 preclinical focus
Lead immuno-oncology program positioned around CCR8 biology, TME modulation, and solid tumor relevance.
BIRAC-BIG supported work
Next-generation antivenom development supported by BIRAC-BIG, strengthening non-dilutive validation.
PrecinAb™ + OptinAb™
Complementary AI/ML and experimental discovery engines support precision antibody design and optimization.
Strategic collaboration ready
Open to licensing, co-development, investment, and oncology-focused partnership discussions.
Collaborate with us
Strategic partnerships & investment
Seeking strategic partners for MGX-101, including licensing, co-development, and investment opportunities
Out-licensing
Partnering opportunities around therapeutic and diagnostic antibody programs.
Co-development
Collaborations to accelerate IO assets and complex-target antibody discovery.
Strategic investment
Investment to advance the lead CCR8 program and scale discovery platforms.
Our Current Partners
Headquarters
4th Floor, AIC-CCMB
Hyderabad, Telangana, India, 500039